Oxurion: Funding, Investors & Team (Sep 2026)
Oxurion is a biopharmaceutical company focused on developing advanced eye treatments to improve vision in patients with conditions like diabetic macular edema, wet age-related macular degeneration, and retinal vein occlusion.
Oxurion has raised $15.8M across 4 funding rounds on record, the most recent an undisclosed round of $330k announced in Mar 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Oxurion Company Profile and Key Stats
Latest funding round on record: Mar 2024.
Oxurion Funding Rounds
Oxurion raised $11.5M in a Post-IPO Equity announced in Mar 2022.
1 years later, an undisclosed round of $3.0M was announced in Mar 2023.
6 months later, an undisclosed round of $1.0M was announced in Sep 2023.
6 months later, an undisclosed round of $330k was announced in Mar 2024.
Oxurion Founders and Leadership Team
Contact details for the Oxurion team: 3 of 4 have an email address on file.
Start 14-day free trial →Oxurion Funding Compared to Other Biotechnology Startups
Oxurion's latest round of $330k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Oxurion in Biotechnology and Heverlee
Companies Similar to Oxurion
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.
Nyxoah is a health-technology company focused on the development and commercialization of innovative…
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in…
neuroClues provides easy-to-use eye-tracking environment to help practitioners instantaneously quantify their…
Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells,…
Confo Therapeutics is a company focused on drug discovery, specifically targeting GPCRs to address medical…
Animab is a biotech company that focuses on developing unique technology to enhance the health of livestock.…
Augustine Therapeutics company is conducting two drug discovery programs in order to discover new generations…
4Tissue is a company focused on research and clinical trials that creates remedies to address the challenges…
Tavira Therapeutics creates an innovative platform to improve the delivery of genes using AAV. By adding…
AgomAb is creating sub-atomic treatments for the recovery of harmed tissues. Their exceptional agonistic…
Oxurion Funding FAQs
What does Oxurion do?
Oxurion is a biopharmaceutical company focused on developing advanced eye treatments to improve vision in patients with conditions like diabetic macular edema, wet age-related macular degeneration, and retinal vein occlusion.
How much funding has Oxurion raised?
Oxurion has raised $15.8M across 4 rounds on record. The most recent is an undisclosed round of $330k announced in Mar 2024.
When did Oxurion last raise funding?
Oxurion's most recent funding round on record is an undisclosed round of $330k, announced in Mar 2024.
Who founded Oxurion?
FundedIQ lists Michael Dillen (Founder), Pascal Ghoson (Founder) at Oxurion.
Who is the CEO of Oxurion?
Patrik De Haes is listed as CEO at Oxurion.
Where is Oxurion headquartered?
Oxurion is based in Heverlee, Vlaams-Brabant, Belgium.
How many employees does Oxurion have?
Oxurion is in the 51-100 employee band.
How does Oxurion's funding compare to other Biotechnology startups?
Oxurion's latest round of $330k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Oxurion Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Oxurion is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.